These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 19112939)
1. Carboplatin and oral cyclophosphamide combination after temozolomide failure in malignant gliomas. Yaman E; Buyukberber S; Uner A; Coskun U; Yamac D; Ozturk B; Kaya AO; Yildiz R; Benekli M; Tumori; 2008; 94(5):674-80. PubMed ID: 19112939 [TBL] [Abstract][Full Text] [Related]
2. Phase I trial of temozolomide using an extended continuous oral schedule. Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665 [TBL] [Abstract][Full Text] [Related]
3. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Donfrancesco A; Jenkner A; Castellano A; Ilari I; Milano GM; De Sio L; Cozza R; Fidani P; Deb G; De Laurentis C; Inserra A; Dominici C Acta Paediatr Suppl; 2004 May; 93(445):6-11. PubMed ID: 15176712 [TBL] [Abstract][Full Text] [Related]
4. Temozolomide in paediatric high-grade glioma: a key for combination therapy? Verschuur AC; Grill J; Lelouch-Tubiana A; Couanet D; Kalifa C; Vassal G Br J Cancer; 2004 Aug; 91(3):425-9. PubMed ID: 15266331 [TBL] [Abstract][Full Text] [Related]
5. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. Korones DN; Smith A; Foreman N; Bouffet E Pediatr Blood Cancer; 2006 Jul; 47(1):37-41. PubMed ID: 16047359 [TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas. van Vugt VA; Piccioni DE; Brown BD; Brown T; Saria MG; Juarez T; Kesari S CNS Oncol; 2014 Jul; 3(4):257-65. PubMed ID: 25286037 [TBL] [Abstract][Full Text] [Related]
8. Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report. Newton HB; Stevens C; Santi M J Neurooncol; 2001 Dec; 55(3):179-84. PubMed ID: 11859973 [TBL] [Abstract][Full Text] [Related]
10. Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity. Lashkari HP; Saso S; Moreno L; Athanasiou T; Zacharoulis S J Neurooncol; 2011 Nov; 105(2):135-47. PubMed ID: 21748491 [TBL] [Abstract][Full Text] [Related]
11. Ifosfamide, carboplatin and etoposide in recurrent malignant glioma. Schäfer N; Tichy J; Thanendrarajan S; Kim Y; Stuplich M; Mack F; Rieger J; Simon M; Scheffler B; Boström J; Steinbach JP; Herrlinger U; Glas M Oncology; 2011; 80(5-6):330-2. PubMed ID: 21791942 [TBL] [Abstract][Full Text] [Related]
12. A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study†. Chintagumpala M; Eckel SP; Krailo M; Morris M; Adesina A; Packer R; Lau C; Gajjar A Neuro Oncol; 2015 Aug; 17(8):1132-8. PubMed ID: 25854526 [TBL] [Abstract][Full Text] [Related]
13. Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment. Yaman E; Buyukberber S; Uner A; Coskun U; Akmansu M; Benekli M; Yamac D; Ozturk B; Kaya AO; Yildiz R; Ozkan S; Gunel N Onkologie; 2008 Jun; 31(6):309-13. PubMed ID: 18547971 [TBL] [Abstract][Full Text] [Related]
14. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. Silvani A; Eoli M; Salmaggi A; Lamperti E; Maccagnano E; Broggi G; Boiardi A J Neurooncol; 2004 Jan; 66(1-2):203-8. PubMed ID: 15015788 [TBL] [Abstract][Full Text] [Related]
15. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. Tosoni A; Franceschi E; Ermani M; Bertorelle R; Bonaldi L; Blatt V; Brandes AA J Neurooncol; 2008 Sep; 89(2):179-85. PubMed ID: 18431544 [TBL] [Abstract][Full Text] [Related]
16. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431 [TBL] [Abstract][Full Text] [Related]
17. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Balmaceda C; Peereboom D; Pannullo S; Cheung YK; Fisher PG; Alavi J; Sisti M; Chen J; Fine RL Cancer; 2008 Mar; 112(5):1139-46. PubMed ID: 18246536 [TBL] [Abstract][Full Text] [Related]
18. "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center. Galldiks N; Berhorn T; Blau T; Dunkl V; Fink GR; Schroeter M J Neurooncol; 2013 Apr; 112(2):209-15. PubMed ID: 23299464 [TBL] [Abstract][Full Text] [Related]
19. Temozolomide and radiotherapy as first-line treatment of high-grade gliomas. Corsa P; Parisi S; Raguso A; Troiano M; Perrone A; Cossa S; Munafò T; Piombino M; Spagnoletti G; Borgia F Tumori; 2006; 92(4):299-305. PubMed ID: 17036520 [TBL] [Abstract][Full Text] [Related]